Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0ecada3d91884deea63029a3e31397a |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21007 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
filingDate |
2016-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2022-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b375b0660ad991d40c86adcb2871d0c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_791f7da6a90cd9ae0541fc294eb80935 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c7919c306d42693774cbf6310474c60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6fd8dfab7a958a07b443e595524cba40 |
publicationDate |
2022-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-11291711-B2 |
titleOfInvention |
Plasminogen replacement therapy for plasminogen-deficiency |
abstract |
Subjects of the invention are a method of plasminogen supplementation in a plasminogen-deficient subject, and method for the treatment of plasminogen-deficiency in a plasminogen-deficient subject. These methods comprise administering to the plasminogen-deficient subject a dose of plasminogen, and more particularly Glu-plasminogen, for increasing the subject plasminogen activity level by at least about 1%, and more particularly by at least 10%, of the normal plasminogen activity and for maintaining the plasminogen activity level over a supplementation period or a treatment period. The plasminogen-deficient subject of the present invention may suffer from Type-I, Type-II plasminogen-deficiency or an acquired deficiency. |
priorityDate |
2015-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |